We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Tradjenta sNDA for Indication as Add-On Diabetes Therapy
FDA Approves Tradjenta sNDA for Indication as Add-On Diabetes Therapy
August 24, 2012
The FDA has approved a new indication for Boehringer Ingelheim and Eli Lilly’s Tradjenta as an add-on therapy to insulin in Type 2 diabetes.